Miracor Medical

Miracor Medical is a private, clinical-stage medical device company pioneering a novel interventional cardiology therapy called Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO). The company's lead PiCSO® Impulse System is designed as a first-line adjunct therapy during primary PCI to reduce infarct size and improve outcomes for heart attack patients, targeting a significant unmet need. With FDA IDE approval for a pivotal U.S. study secured in 2022 and a strong, experienced leadership team, Miracor is advancing towards key clinical milestones. The company is currently pre-revenue, having raised €24 million in 2020 to fund its clinical development programs.

Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) - a catheter-based system that intermittently occludes the coronary sinus to potentially improve microvascular perfusion and reduce infarct size during PCI for acute myocardial infarction.

PiCSO faces competition from other investigational pharmacological and device-based adjunct therapies aimed at reducing reperfusion injury and infarct size. It competes within the broader interventional cardiology device market dominated by large players. Its unique venous system mechanism may provide differentiation, but it must prove superior or complementary efficacy.